| Xie, Li xin |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
NCT05638269: A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China |
|
|
| Recruiting | N/A | 12000 | RoW | no intervention | Zhujiang Hospital, National Natural Science Foundation of China | Essential Hypertension, Liver Cancer, Nasopharyngeal Cancer, Pancreatic Cancer, Lung Cancer, Chronic Kidney Diseases, Acute Coronary Syndrome, Epilepsy, Gastric Cancer, Primary Aldosteronism, Subclinical hypothyroïdism | 12/24 | 12/25 | | |
| Li, Xin |
| Active, not recruiting | 4 | 948 | Europe, Canada, US, RoW | Edoxaban, Lixiana, Savaysa, Non-anticoagulant medical therapy | Population Health Research Institute | Intracranial Hemorrhages, Atrial Fibrillation | 04/26 | 10/26 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT04025164: Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery |
|
|
| Recruiting | 3 | 4052 | RoW | Hypofractionated Radiotherapy, Experimental Arm, Conventional fractionated Radiotherapy, Standard Arm | Fudan University | Breast Cancer | 06/23 | 06/28 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recruiting | 2 | 120 | RoW | TQH3906 capsules, Placebo of TQH3906 capsules | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Plaque Psoriasis | 01/25 | 09/25 | | |
NCT06601504: Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 60 | RoW | HMPL-760 planned dose 1, R-GemOx, Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2 | Hutchmed | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 05/26 | 11/26 | | |
NCT05768529: Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 1/2 | 100 | RoW | U16 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Relapsed or Refractory Non-Hodgkin's Lymphoma | 12/24 | 12/26 | | |
NCT04673799: Comparing of the Pharmacokinetics, Immunogenicity and Safety of MV088 and Prolia® in Healthy Adults. |
|
|
| Not yet recruiting | 1 | 144 | NA | MV088 injection, Prolia® injection | Kunming Pharmaceuticals, Inc. | Healthy | 10/21 | 10/21 | | |
| Completed | 1 | 100 | RoW | AK104 (before the change), AK104 (after the change) | Akeso | Healthy Male Subjects | 03/23 | 04/23 | | |
NCT05758428: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects |
|
|
| Completed | 1 | 28 | RoW | Ensifentrine, Placebo | Nuance Pharma (shanghai) Co., Ltd | Chronic Obstructive Pulmonary Disease | 04/23 | 04/23 | | |
GNC-035-103, NCT05160545: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 1 | 29 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer | 06/25 | 12/25 | | |
| Recruiting | 1 | 152 | RoW | Recombinant CD20 monoclonal antibody-MMAE conjugte for injection, TRS005 | Zhejiang Teruisi Pharmaceutical Inc. | CD20-positive B-cell Non-Hodgkin Lymphoma | 12/23 | 12/24 | | |
NCT05505812: Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer |
|
|
| Not yet recruiting | 1 | 10 | RoW | HS-IT101 | The Affiliated Hospital of Qingdao University, Qingdao Sino-Cell Biomedicine Co.,Ltd. | Breast Cancer | 12/23 | 03/27 | | |
| Not yet recruiting | 1 | 12 | RoW | NTQ5082 capsule | Nanjing Chia-tai Tianqing Pharmaceutical | Complement-mediated Hemolytic Diseases | 12/24 | 02/25 | | |
NCT06560593: A Phase 1 Clinical Trial of NTQ5082 in Healthy Volunteers |
|
|
| Not yet recruiting | 1 | 82 | RoW | NTQ5082, Placebo | Nanjing Chia-tai Tianqing Pharmaceutical | Complement-mediated Hemolytic Diseases | 12/24 | 02/25 | | |
NCT06196060: Improving ToM in Children With ASD Through VPT Training: Behavioral and fNIRS Study |
|
|
| Recruiting | N/A | 100 | RoW | Visual perspective taking training, Block building training, Thought-bubble training, Treatment as usual | Nanjing Normal University, Zhuhai Fudan Innovation Institute, Second Affiliated Hospital of Guangxi Medical University | Autism Spectrum Disorder | 06/24 | 09/24 | | |
NCT06579976: Multimodal High-frequency Ultrasound-based Study of Plaque Psoriasis Severity Index |
|
|
| Not yet recruiting | N/A | 45 | RoW | No intervention | Shanghai Yueyang Integrated Medicine Hospital | Plaque Psoriasis | 02/25 | 05/25 | | |
NCT05665010: Precise Stratification of Genetic Risk of Ovarian Function Impairment |
|
|
| Recruiting | N/A | 1000 | RoW | Genetic susceptibility | Tongji Hospital | Premature Ovarian Insufficiency, Diminished Ovarian Reserve, Early Menopause | 10/23 | 10/24 | | |
| Xian, Lei |
| Not yet recruiting | N/A | 342 | RoW | Osimertinib, Alectinib, TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy | Guangdong Association of Clinical Trials, Nanjing Geneseeq Technology Inc. | Non-Small Cell Lung Cancer | 01/29 | 01/32 | | |
NCT04830826: A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China |
|
|
| Recruiting | N/A | 2000 | RoW | Surgeries | The First Affiliated Hospital of Guangzhou Medical University | NSCLC, Stage I, NSCLC, Stage II, NSCLC, Stage III | 01/24 | 07/24 | | |
| li, Meiling |
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. |
|
|
| Recruiting | 2 | 144 | RoW | Iguratimod, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Primary Sjögren Syndrome | 04/22 | 06/22 | | |
NCT05685966: Retrospective Study of COVID-19 on Reproductive Function |
|
|
| Recruiting | N/A | 400 | RoW | no intervention | Jinling Hospital, China | COVID-19 | 03/23 | 01/24 | | |
NCT05685992: Novel Coronavirus Infection and Reproductive Function |
|
|
| Recruiting | N/A | 400 | RoW | no intervention | Jinling Hospital, China | COVID-19 Infection | 01/24 | 01/24 | | |
| Lai, Yinghui |
TE-ITP, NCT05583838: A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts |
|
|
| Completed | 4 | 157 | RoW | rhTPO, Recombinant human thrombopoietin, TPIAO, Eltrombopag, Eltrombopag olamine | Institute of Hematology & Blood Diseases Hospital, China, The Second Hospital of Hebei Medical University, Xijing Hospital, The Affiliated Hospital of Inner Mongolia Medical University, The Second Affiliated Hospital of Kunming Medical University, Second Affiliated Hospital of Guangzhou Medical University, Shaanxi Provincial People's Hospital, Henan Cancer Hospital, North China University of Science and Technology Affiliated Hospital, The Second Affiliated Hospital of Dalian Medical University, Second Hospital of Shanxi Medical University, The Second Affiliated Hospital of Harbin Medical University, Shenyang Sunshine Pharmaceutical Co., LTD., First Affiliated Hospital of Xinjiang Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, Kashgar 1st People's Hospital, Xi'an Central Hospital, Beijing Public Health Foundation, Yuyao People's Hospital of Zhejiang Province | Previously Treated Primary Immune Thrombocytopenia | 02/24 | 07/24 | | |
| Recruiting | N/A | 300 | RoW | PCR was used to detect pneumocystis in respiratory specimens | First Affiliated Hospital of Guangxi Medical University, The People's Hospital of Guangxi Zhang Autonomous Region, The Fourth People's Hospital of Nanning, Chest Hospital of Guangxi Zhuang Autonomous Region, People's Hospital of Baise, LiuZhou People's Hospital, The second Nanning People's Hospital, The People's Hospital of Wuzhou, Maternal and Child Health Care of Guangxi Zhuang Autonomous Region, Second Affiliated Hospital of Guangzhou Medical University, 923rd Hospital of the People's Liberation Army | Immunocompromised Patients, Pneumocystis Pneumonia, Diagnosis, Polymerase Chain Reaction | 12/22 | 06/23 | | |
| SUN, XUYONG |
NCT06114953: Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients |
|
|
| Recruiting | 4 | 152 | RoW | Mizoribine, Mycophenolate Mofetil, Mycophenolate Acid | Lee's Pharmaceutical Limited | Kidney Transplant Immunosuppression | 01/25 | 03/25 | | |
| Huang, Jinghao |
NCT06030804: Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery |
|
|
| Recruiting | N/A | 4532 | RoW | Dexmedetomidine, Dexmedetomidine hydrochloride, Placebo, Normal saline | Peking University First Hospital, Peking University | Elderly, Cancer Surgery, Dexmedetomidine, Long-Term Survivors | 09/25 | 10/28 | | |
